In line with our unwavering commitment to strengthening India’s industrial and innovation ecosystem, Finraja is proud to have successfully provided end-to-end advisory and facilitation support to Nitika Pharmaceutical Specialties Pvt. Ltd., Nagpur, enabling them to secure financial assistance of ₹82.61 crore from the Technology Development Board (TDB), Department of Science and Technology (DST), Government of India. This support has been extended for Nitika’s ambitious project titled “Manufacture of Complex Excipients,” which is crucial for advancing India’s self-reliance in pharmaceutical manufacturing.

Offered at an effective interest rate of just 2.50%, this financial package will help Nitika establish a state-of-the-art manufacturing facility for the commercial production of 14 advanced, high-value pharmaceutical excipients. These excipients—while pharmacologically inactive—are essential for the performance, stability, and bioavailability of modern drug formulations, especially in the evolving landscape of complex generics and biopharmaceuticals.

The project is also aligned with the Government of India’s Production Linked Incentive (PLI) scheme for pharmaceuticals, under which Nitika has been selected as a beneficiary under Group C – MSME (Pharmaceuticals). This reflects the strategic importance of the initiative in boosting domestic capabilities and reducing India’s dependency on critical imported inputs.

Finraja takes immense pride in being a trusted partner for industries across India. For over 25 years, we have been at the forefront of facilitating Central and State Government subsidies, incentives, grants, and financial assistance across various sectors, including Pharmaceuticals, Logistics, Tourism, Agriculture, Infrastructure, and MSMEs.